Medical/Pharmaceuticals
Gene Solutions Strengthens China Footprint with Strategic Partnerships in Precision Oncology
BEIJING, June 20, 2025 /PRNewswire/ -- Gene Solutions
The Department of Health - Abu Dhabi and Abbot Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi
Reinforcing Abu Dhabi's position as a global life science hub
ABU DHABI, UAE, June 20, 2025 /PRNewswire/ -- During BIO International
Convention in Boston USA, theDepartment of Health – Abu Dhabi
Cochlear celebrates 30 Years in China and the launch of the world's first and only smart hearing implant system
* The new Cochlear™ Nucleus® Nexa™ System is the first and only hearing implant featuring internal memory and upgradeable firmware.1+ * This year marks the 30-year anniversary since the first adult cochlear implant surgery in mainland China which took place in 1995. * Nearly 10 million peopl...
Ottai Unveils Revolutionary AI-Powered Biosensor Set to Transform Chronic Disease Care
Groundbreaking Technology Empowers Patients to Take Control of Their Health HONG KONG, June 20, 2025 /PRNewswire/ -- Ottai, an Oxford-originated pioneer in AI digital health innovation, today announced the launch of its next-generation AI-powered wearable designed to revolutionize chronic diseas...
Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations
SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based doublet chemotherapies as a first-line treatment for...
The Department of Health - Abu Dhabi and Sanofi Forge Strategic Alliance to Accelerate the Development of New Global Vaccines in Abu Dhabi
On the sidelines of a high-level US visit focused on healthcare innovation
ABU DHABI, UAE, June 19, 2025 /PRNewswire/ -- The Department of Health – Abu
Dhabi
111, Inc. Announces First Quarter 2025 Unaudited Financial Results
* Maintained Quarterly Operational Profitability * Operating Expenses as a Percentage of Revenues Decreased 30 Basis Points YoY * Maintained Quarterly Positive Operating Cash Flow SHANGHAI, June 19, 2025 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled h...
Immuno Cure and PharmaJet Announce Collaboration to Advance a Novel HIV Therapeutic DNA Vaccine Using Needle-Free Technology in Humans
HONG KONG, June 19, 2025 /PRNewswire/ -- Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce its upcoming collaboration with PharmaJet® to evaluate the safety and immunogenicity of HIV therapeutic DNA vaccine, ICVAX, de...
Novo Holdings Reports Strong Momentum in Asia Across Healthcare and Planetary Health in 2024
Landmark investments, portfolio progress, and expanded presence position Novo Holdings for long-term growth and impact in Asia SINGAPORE, June 19, 2025 /PRNewswire/ -- Novo Holdings today released its Asia Investments Year in Review 2024, highlighting a year of strategic growth and purpose-driven...
MALAYSIA HIGHLIGHTS MEDICAL AND TOURISM SYNERGY AT THE MALAYSIA HEALTHCARE EXPO MAKASSAR 2025
Over 15 Malaysian hospitals and Tourism Selangor spotlight world-class care and vibrant recovery tourism for Indonesian patients, led by the Malaysia Healthcare Travel Council KUALA LUMPUR, Malaysia, June 19, 2025 /PRNewswire/ -- The Malaysia Healthcare Travel Council (MHTC), in collaboration w...
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma
SHANGHAI, June 18, 2025 /PRNewswire/ -- Simcere Zaiming, an innovative
oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today
announced the first US patient has started treatment in the ongoing Phase 1
trial (SIM0500-101,NCT06375044
LOTTE BIOLOGICS Signs Antibody Manufacturing Contract with Ottimo Pharma
* Expanding track record by signing contracts with various global companies across Asia and Europe SEOUL, South Korea, June 18, 2025 /PRNewswire/ -- LOTTE BIOLOGICS announced on June 19, 2025 that it has signed a contract manufacturing agreement for antibody therapeutics with Ottimo Pharma, a ...
MedHub-AI Receives PMDA Approval in Japan for AutocathFFR®
TEL AVIV, Israel, June 18, 2025 /PRNewswire/ -- MedHub-AI
Frost & Sullivan Names Dassault Systèmes as Recipient of Its 2025 Global Transformational Innovation Leadership Award for Excellence in Smart Manufacturing Life Sciences Solutions
Recognized for its leadership in driving digital transformation and sustainable innovation through virtual twin technology in the life sciences manufacturing sector. SAN ANTONIO, June 19, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce thatDassault Systèmes has been awarded the 2025...
Backed by $2 Million, Droplet IV is Set to Launch its Revolutionary Automatic IV-Line Flushing Device in EU & US in 2026
COPENHAGEN, Denmark, June 18, 2025 /PRNewswire/ -- Droplet IV today announced the successful completion of a $2 million funding round to enable launch of its first automatic IV-line flushing device in the EU and US markets. The device addresses a critical need among nurses, who currently spend si...
Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer
Strategic appointments reflect Medison's continued investment in global scale
and operational excellence
PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ -- Medison
Medison Expands Global Leadership Team with Chief Business Officer and Chief Legal & Compliance Officer
Strategic appointments reflect Medison's continued investment in global scale
and operational excellence
PETACH TIKVA, Israel, June 18, 2025 /PRNewswire/ -- Medison
Paradigm Therapeutics, Inc. Announces an Additional Investment by Eshelman Ventures, LLC to Expedite Global Development and Global Registration of SD-101, A Topical Therapy for Treatment Across the Entire Skin Surface of All Subtypes of Epidermolysis Bullosa (EB)
First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing Development of SD-101 and Commercial Launch of the SD-101 Program Globally. MT PLEASANT, S.C.,...
Embla Medical Recognized for Leadership in Accessibility and International Reach
Company honored by Forbes Magazine for Championing Accessibility and by Iceland's President for Excellence in Global Exports REYKJAVÍK, Iceland, June 18, 2025 /PRNewswire/ -- Embla Medical (NASDAQ Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, is being internati...
Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program
PERTH, Australia, June 18, 2025 /PRNewswire/ -- Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, today announced a landmark partnership with Medibank, Australia's largest private health insurer. Under the multi-yea...
Week's Top Stories
Most Reposted
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 278 media titles]
2025-12-26 12:55ACEN completes transition to 100% renewable energy
[Picked up by 273 media titles]
2025-12-29 18:53CYFIRMA's 2025 Impact Recap Showcases DeCYFIR, Preemptive External Threat Landscape Management Platform, Delivering Measurable Global Defense Against Emerging Threats
[Picked up by 262 media titles]
2025-12-29 09:00ChinaAMC launches Depository Receipts of two Chinese flagship ETFs in Thai exchange
[Picked up by 259 media titles]
2025-12-29 14:27"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54